Skip to main content
European Commission logo print header

Multimodal glycoconjugates: a molecular Lego approach for antitumoral immunotherapy

Descrizione del progetto

Un approccio innovativo all’immunoterapia contro il cancro attraverso il reindirizzamento degli anticorpi endogeni contro le cellule tumorali

L’immunoterapia mirata è un’alternativa ideale ai trattamenti oncologici standard. Tuttavia, è disponibile un numero molto limitato di applicazioni e restano da risolvere numerosi problemi relativi all’intero approccio. Il progetto LEGO, finanziato dal CER, intende creare un nuovo paradigma di trattamento attraverso un programma interdisciplinare per sviluppare strutture biomolecolari intelligenti con una complessità e proprietà immunologiche senza precedenti contro il cancro. L’obiettivo è quello di introdurre un approccio molecolare LEGO altamente innovativo per progettare molecole sintetiche in grado di reindirizzare gli anticorpi endogeni nel flusso sanguigno per attaccare i tumori senza la necessità di un’immunizzazione preliminare. L’eliminazione efficiente del cancro da parte degli effettori immunitari sarà realizzata da molecole selezionate in vitro che combinano moduli innovativi di legame tra anticorpi e tumori.

Obiettivo

Despite significant progress in cancer therapy, current treatments are still controversial due to intolerable side effects. Targeted immunotherapy has recently emerged as an ideal alternative to improve treatment modalities for cancers patients. However, very limited approaches are available today and major issues remain to be addressed. The ERC grant offers a unique opportunity to propose a new paradigm for treating cancer. Through a ground-breaking interdisciplinary program, at the crossroad of supramolecular chemistry, synthetic chemistry, molecular engineering, biophysics, biochemistry, immunochemistry and glycoscience, it is my ambition to design, synthesize and study smart biomolecular structures with unprecedented combinations, complexity and immunological properties against cancers. To achieve this purpose, I will develop a “molecular LEGO” approach to construct synthetic molecules capable of redirecting endogenous antibodies present in the human bloodstream against tumors without preliminary immunization. Efficient tumoral killing by immune effectors will be provided by molecules combining innovative antibody and tumor binding modules that will be selected in vitro beforehand. To be successful, I will address fundamental questions that are still unresolved in chemical and biological sciences. The expected breakthroughs will represent a landmark achievement in these fields and will open promising horizons in cancer immunotherapy. Beyond this, it can be expected that our findings will pave the way to future development of synthetic molecules embedded with recognition, labeling, and/or therapeutic functions. They will thus find wider medicinal, diagnostic and even theranostic applications for which the development of more effective and selective biomolecular systems is of the utmost importance.

Meccanismo di finanziamento

ERC-COG - Consolidator Grant

Istituzione ospitante

UNIVERSITE GRENOBLE ALPES
Contribution nette de l'UE
€ 1 946 150,00
Indirizzo
621 AVENUE CENTRALE
38058 Grenoble
Francia

Mostra sulla mappa

Regione
Auvergne-Rhône-Alpes Rhône-Alpes Isère
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 2 000 000,00

Beneficiari (2)